Three Small-Cap Biotech Stocks To Consider Now
Biotech stocks offer investors a clear risk/reward proposition.Investors should look at the company’s clinical focus and its pipeline.This clinical-stage immuno-oncology company’s stock is up over 135% after announcing updated interim data in a Phase 1 trial for its leading therapeutic.This pre-clinical company is surging as investors are beginning to speculate on the sector.This company’s stock is up more than 400% in 2022 as it is waiting for results in a Phase 3 clinical trial.Small-cap biotech stocks are among the riskiest of stocks for investors to own. One reason is that many of these co...